Monitor the company's cash burn rate and whether this loan is sufficient to fund operations until potential revenue milestones. The 8-month interest-only period provides near-term liquidity relief but the 110% amortization and 10% prepayment penalty add to the cost of capital.
Price Chart
Executive Summary
Northwest Biotherapeutics entered into a $5,505,000 commercial loan agreement with Streeterville Capital, LLC on October 26, 2026. The loan has a 22-month maturity, 8% annual interest, a 10% original issue discount, and no repayments for the first 8 months. Proceeds will fund ongoing business operations, indicating the company continues to rely on debt financing to support its cash needs.
Key Financial Metrics
Key Facts
- Loan principal of $5,505,000 from Streeterville Capital, LLC
- 22-month maturity with no repayments for first 8 months
- 14 equal monthly installments of principal at 110% of pro rata amount starting June 26, 2027
- Interest rate of 8% per annum
- 10% original issue discount
- Pre-payment allowed with a 10% charge
- Funds used for ongoing business operations
Financial Impact
New debt obligation of $5,505,000 with effective cost above 8% due to 10% OID and 110% amortization factor; net proceeds after OID approximately $4,954,500.
Risk Factors
- High-cost debt with 10% OID and 110% amortization increases financial burden
- Reliance on debt for operations suggests limited internal cash generation
- Potential dilution risk if the lender converts or if additional financing is needed
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-120669 |
| Document: 0001104659-26-120669-index-headers.html | 0001104659-26-120669 |
| Document: 0001104659-26-120669-index.html | 0001104659-26-120669 |
| Document: 0001104659-26-120669.txt | 0001104659-26-120669 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 30, 2026 2d ago | 8-K | $0.1700 | awaiting T+60 | awaiting T+60 | $0.1700 (−0.00%) |
Jul 31, 2026 13w ago | 424B5 | $0.1600 $0.1650 | ▼ −3.13% | ▼ −1.34% | $0.1700 (−6.25%) |
Apr 21, 2026 27w ago | EFFECT | $0.1900 $0.1534 | ▼ −19.26% | ▼ −26.16% | $0.1700 (−10.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers